Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase EARLY_PHASE1
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Patients with newly diagnosed primary estrogen-receptor (ER) positive breast cancer, with at least one breast lesion that is 1.0 cm in diameter or greater, may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 20 evaluable subjects will participate in a single imaging cohort. Study subjects will undergo imaging of the breast with a novel device combining dedicated Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DBT) following intravenous injection of \[18F\]-Fluoroestradiol (FES). This is an observational study; FES-BPET/DBT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the FES-BPET/DBT results, treatment decisions are made by the treating physicians based upon standard clinical imaging.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: BPET/DBT imaging — Imaging of the breast with a novel device combining dedicated Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DBT) following intravenous injection of \[18F\]-Fluoroestradiol (FES).
  • Drug: 18F-FES — Radiolabelled fluoroestradiol for PET imaging

Primary Outcomes

  • Uptake of FES on BPET (6 weeks)
  • Image quality (6 weeks)
  • Image artifacts (6 weeks)
  • Parenchymal appearance (6 weeks)
  • Tumor size and extent (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2023-10-02
Completion: 2028-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Abramson Cancer Center at Penn Medicine
Principal Investigators:
  • Christine Edmonds, MD (PRINCIPAL_INVESTIGATOR) - Abramson Cancer Center at Penn Medicine
Contact Information
Study Contact:
Erin o Schubert
2155736569
erin.schubert@pennmedicine.upenn.edu
Hannah Straughn
hannah.straughn@pennmedicine.upenn.edu
Erin Schubert
215-753-6569
erin.schubert@pennmedicine.upenn.edu
University of Pennsylvania
Interventions
  • Device: BPET/DBT imaging — Imaging of the breast with a novel device combining dedicated Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DBT) following intravenous injection of \[18F\]-Fluoroestradiol (FES).
  • Drug: 18F-FES — Radiolabelled fluoroestradiol for PET imaging
Study Locations (1 sites)
University of Pennsylvania, Philadelphia, Pennsylvania 19130 United States
Eligibility Criteria
Inclusion Criteria: 1. Participants will be ≥ 18 years of age. 2. Known ER positive (by immunohistochemistry) breast cancer. 3. At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. mammogram, ultrasound, MRI, CT, FDG-PET/CT). Only one type of imaging is required to show a lesion. 4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria: 1. Females who are pregnant or breast feeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential prior to PET imaging.. 2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician. 3. Currently taking tamoxifen or raloxifene 4. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.
Conditions Depression in Adolescence
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research will use biobehavioral approaches to generate understanding about the linkages between sleep duration and timing, stressful life events, and depressive symptoms in adolescents, with a long-term aim of developing effective preventative interventions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Sleep extension and advance — Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses ("blue blockers") beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
  • Behavioral: Regular sleep duration and timing — Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.

Primary Outcomes

  • Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Depression Scale - Short Form (8-item) (2 months)
  • Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Positive Affect Scale - Short Form (8-item) (2 months)
  • Dimensional Anhedonia Rating Scale (DARS) (2 months)
  • Reward-related brain function (2 weeks)
  • Stress-related brain function (2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-27
Completion: 2026-12-31
Eligibility
Age: 14 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Oregon
Collaborators: Oregon Research Institute, University of Pittsburgh, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Melynda D Casement, PhD (PRINCIPAL_INVESTIGATOR) - University of Oregon
Contact Information
Study Contact:
Amanda Johnson
541-346-4107
anj@uoregon.edu
Melynda D Casement
5413467051
casement@uoregon.edu
University of Oregon
Interventions
  • Behavioral: Sleep extension and advance — Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses ("blue blockers") beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
  • Behavioral: Regular sleep duration and timing — Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
Study Locations (1 sites)
University of Oregon, Eugene, Oregon 97403 United States
Eligibility Criteria
Inclusion Criteria: 1. 14-18 years of age 2. Currently in high school 3. short and late sleep (weekday sleep duration ≤ 7 h and bedtime ≥ 22:30 (10:30 pm); n=100) or long and early sleep (weekday sleep duration \> 7 hours and bedtime ≤ 22:30 (10:30 pm); n=50), indexed by the Munich Chronotype Questionnaire 4. Lifetime stressful event frequency ≥ 2 on the Stress and Adversity Inventory (STRAIN) Screener 5. Depressive symptom severity t-score greater than or equal to 45 on the Patient Reported Outcomes (PROMIS) Depression scale 6. English language fluency Exclusion Criteria: 1. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for current moderate to severe alcohol/substance use disorder (≥4 symptoms); 2. Current clinician-provided diagnosis of narcolepsy or idiopathic hypersomnia; 3. Lifetime diagnosis of bipolar or schizophrenia spectrum disorder; 4. Certain medical conditions (e.g., serious neurological disorder, heart failure or serious heart trouble, history of head injury with unconsciousness \> 5 minutes); 5. Conditions that are contraindicated for magnetic resonance imaging (MRI; e.g., ferrous metal in the body); 6. Positive screen for participant-reported eye disease, epilepsy, or photosensitizing medications that are contraindicated during the manipulation condition when bright light is administered (e.g., psychiatric neuroleptic drugs \[e.g., phenothiazine\], psoralen drugs, antiarrhythmic drugs \[e.g., amiodarone\], antimalarial and antirheumatic drugs, porphyrin drugs used in photodynamic treatment of skin diseases); 7. Use of melatonin if participant is not willing to discontinue use for the duration of the study. We will schedule around (i.e., delay appointments as needed) to avoid the timeframe of the following events: 1. urgent suicide risk, defined by moderate/severe risk per Columbia Suicide Severity Rating Scale (CSSRS) and clinician determination that current risk requires immediate action; 2. travel across two or more time zones within the month prior to the overnight study visits; 3. beginning or ending a prescribed medication within 2 months of the observational study; 4. prescribed medication dose changes within the timeframe calculated as 5x the drug's half-life \[the time to reach pharmacokinetic steady-state\] before the initiation of the observational or experimental studies; 5. anticipated change in prescribed medications or medication dosing during the observational or experimental studies; 6. current symptoms of airborne infectious illness prior to laboratory visits. Participants with positive breathalyzer screen (blood alcohol level \> .02) will be rescheduled for an alternative overnight visit date.
Conditions Cognitive Dysfunction, Stroke, Dementia,...
Phase Not Applicable
Enrollment 140
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to determine the feasibility of using integrated Transcranial Doppler Ultrasonography or Near Infrared Spectroscopy to detect changes in cerebral autoregulation and neurovascular coupling in healthy, stroke, dementia, depression and delirium populations. We also aim to: * Determine the optimal stimulus for neurovascular coupling * To derive sample size estimates for a future study * To develop a multilevel, multivariate model that can be applied to future datasets

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • Good quality TCD-NIRS data (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-03-17
Completion: 2026-08-26
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: true
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Leicester
Principal Investigators:
  • Dr Jatinder Minhas (PRINCIPAL_INVESTIGATOR) - Clinical Associate Professor of Stroke Medicine
Contact Information
Study Contact:
James Ball
07551300119
jdb58@le.ac.uk
Lucy Beishon, MBChB
01162523134
lb330@le.ac.uk
University Hospitals of Leicester NHS Trust
Lucy Beishon, MBChB
University Hospitals of Leicester NHS Trust
Interventions
N/A
Study Locations (2 sites)
University Hospitals of Leicester NHS Trust, Leicester, Leicestershire LE1 5WW United Kingdom
Leicestershire Partnership Trust, Leicester, Leicestershire United Kingdom
Eligibility Criteria
* Inclusion Criteria: * Healthy adults aged over 65 years, free from medical comorbidities or medications that can adversely affect cognitive function or cerebral haemodynamics; * Stable, well controlled comorbidities (e.g. hypertension); * A diagnosis of dementia (major neurocognitive disorder), depression, or delirium, according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria; * Participants on or off anti-dementia drug therapy (acetylcholinesterase inhibitors, NMDA receptor antagonists), and antidepressants; * A diagnosis of ischaemic (IS) or haemorrhagic (ICH) stroke according to clinical and/or radiological findings, within 72 hours of symptom onset * Exclusion Criteria: * Poorly controlled medical comorbidities affecting cerebral haemodynamics or cognitive function (e.g., heart failure, hypertension, type two diabetes); * Clinically unstable or too unwell to cooperate with the study protocol; * Lacks capacity or personal consultee to consent to the study.
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate whether the 12-week health coaching mobile application (LIVEN) will succeed in enhancing lifestyle behaviors in adults with Type 2 Diabetes compared to typical treatment. The mobile application's viability will be assessed in 2 parts; the first part is testing easiness and friendliness of using Liven by the patient and health coach. The second part is evaluating the suitability of Liven education material for the patients and whether the coaching program results in enhancing lifestyle behaviors and blood sugar levels. the investigators hypothesize that the 12-week online lifestyle-coaching program will be viable, and a full-scale study can proceed.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: interactive Mhealth Lifestyle behavior intervention — Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
  • Other: Sham — Receiving standard care, LIVEN educational material and access to the application

Primary Outcomes

  • recruitment rate - descriptive (immediately after the intervention (3 months))
  • retention rates (immediately after the intervention (3 months))
  • User friendliness (Daily application engagement data for each patient will be analyzed once at the end of the patient's 12 week program.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Princess Nourah Bint Abdulrahman University
Collaborators: Liven
Contact Information
Study Contact:
Shaima A Alothman, PhD
+966503952053
shaalothman@pnu.edu.sa
Shaima A Alothman, PhD
+966503952053
shaalothman@pnu.edu.sa
Princess Nourah bint Abdulrahman University
Interventions
  • Behavioral: interactive Mhealth Lifestyle behavior intervention — Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
  • Other: Sham — Receiving standard care, LIVEN educational material and access to the application
Study Locations (1 sites)
Princess Nourah bint Abdulrahman University, Riyadh, Riyadh Region 11321 Saudi Arabia
Eligibility Criteria
Inclusion Criteria: * Adults, aged 18 years or older * Arabic speakers * Capable of utilizing smartphones * Diagnosed with T2DM * Poor glycemic control: A1c \> 7.5% Exclusion Criteria: * Individuals using insulin injection * Individuals suffering from disorders that might affect intervention (e.g. amputation, enucleation of the eye, or end-stage kidney disease) * Women who are pregnant or breastfeeding * Individuals diagnosed with other types of diabetes (such as type I or MODY)
Conditions Breast Neoplasm, Breast Cancer, Hormone ...
Phase PHASE2
Enrollment 620
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: PIK3CA inhibitor — PIK3CA inhibitor
  • Drug: AKT inhibitor — AKT inhibitor
  • Drug: Carrelizumab — Pd-1 mab
  • Drug: Famitinib — VEGFR inhibitor
  • Drug: Fluzoparib — PARP inhibitor
  • Drug: Dalpiciclib — CDK4/6 inhibitor
  • Drug: SHR-A1811 — HER2 ADC
  • Drug: Everolimus — mTOR inhibior

Primary Outcomes

  • Overall response rate (ORR) (Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 3 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-12-30
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 620 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Collaborators: Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University, Nanchang Third Hospital, Liaoning Cancer Hospital & Institute, The First Hospital of Jilin University
Contact Information
Study Contact:
Zhimin Shao, M.D
+86-021-64175590
zhimingshao@yahoo.com
Zhi-Ming Shao, MD
86-21-641755901105
zhimingshao@yahoo.com
Breast cancer institute of Fudan University Cancer Hospital
Lei Fan, MD
86-21-641755901105
cmchen@medmail.com.cn
Breast cancer institute of Fudan University Cancer Hospital
Interventions
  • Drug: PIK3CA inhibitor — PIK3CA inhibitor
  • Drug: AKT inhibitor — AKT inhibitor
  • Drug: Carrelizumab — Pd-1 mab
  • Drug: Famitinib — VEGFR inhibitor
  • Drug: Fluzoparib — PARP inhibitor
Study Locations (1 sites)
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Female aged ≥18 years; 2. HR+/HER2- invasive breast cancer confirmed by histology (specific definition: ER \>10% positive tumor cells by immunohistochemistry is defined as ER positive, PR \>10% positive tumor cells is defined as PR positive, ER and/or PR positive is defined as HR positive; HER2 0-1+ or HER2 + but negative by FISH without amplification was defined as HER2 negative); 3. Locally advanced breast cancer (unable to undergo radical local treatment) or recurrent metastatic breast cancer; 4. HR+/HER2- advanced breast cancer patients who had previously received CDK4/6 inhibitor therapy; 5. At least one measurable lesion according to RECIST 1.1 (conventional CT scan ≥20 mm, spiral CT scan ≥10 mm, measurable lesion has not received radiotherapy); 6. The functions of the main organs are basically normal and meet the following conditions: I. Blood routine examination criteria shall meet: HB ≥90 g/L (no blood transfusion within 14 days); The ANC acuity 1.5 x 109 / L; PLT acuity 75 x 109 / L; Ii. Biochemical tests should meet the following criteria: TBIL ≤1.5×ULN (upper limit of normal value); ALT and AST ≤3×ULN; If liver metastases were present, ALT and AST≤ 5×ULN; Serum Cr ≤1×ULN, endogenous creatinine clearance \> 50 ml/min (Cockcroft-Gault formula); 7. They have not received radiotherapy, molecular targeted therapy, or surgery within 3 weeks before the start of the study, and have recovered from the acute toxicity of previous treatment (if surgery was performed, the wound has healed completely); No peripheral neuropathy or grade I peripheral neurotoxicity; 8. ECOG score ≤2, and life expectancy ≥3 months; 9. Fertile female subjects were required to use a medically approved contraceptive method during the study treatment period and for at least 3 months after the last use of the study drug; 10. Subjects volunteered to join the study, signed informed consent, had good compliance, and cooperated with follow-up. Exclusion Criteria: 1. Radiotherapy (except for palliative causes), chemotherapy, and immunotherapy were used in the first 3 weeks of treatment, except bisphosphonate (which can be used for bone metastasis); 2. Uncontrolled central nervous system metastases (indicating symptomatic or symptomatic treatment with glucocorticoids or mannitol); 3. A history of clinically important or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction, or ventricular arrhythmia within the last 6 months; 4. Persistent grade 1 or higher adverse reactions caused by previous treatments. The exception to this is hair loss or something the researchers don't think should be ruled out. Such cases should be clearly documented in the investigator's notes; 5. Underwent major surgery (except minor outpatient procedures, such as placement of vascular access) within 3 weeks of the first course of trial treatment; 6. Pregnant or lactating patients; Malignancy (except basal cell carcinoma of the skin, which has been cured, and carcinoma in situ of the cervix) in the past 5 years.
Conditions Hypertension, Diabetes Mellitus, Materna...
Phase Not Applicable
Enrollment 19331
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to examine the intervention effectiveness and dissemination of digital health care delivery models for improving selected health outcomes in the Medicaid population.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: digital health delivered multicomponent intervention — The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.

Primary Outcomes

  • Change in participant's blood pressure control at three points in time (3 months, 6 months, 12 months)
  • Change in participant's glycemic control at three points in time (3 months, 6 months, 12 months)
  • Change in Patient Assessment of Chronic Illness Care scale (PACIC) from baseline to exit from program (baseline, end of program, on average of 1 year)
  • Change in Patient Perception of Health Care Management (adapted form of PACIC to reflect pre/postnatal care) from baseline to exit from program (baseline, end of program, on average 6 months)
  • Patient satisfaction, 1-item researcher generated question (at exit from program, on average 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-09-26
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 19331 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: OSF Healthcare System
Principal Investigators:
  • Melinda B Cooling, DNP, APRN (PRINCIPAL_INVESTIGATOR) - OSF Healthcare System
Contact Information
Study Contact:
Colleen J. Klein, PhD, APRN
309-655-3899
colleen.klein@osfhealthcare.org
Melinda B Cooling, DNP, APRN
309-624-4649
melinda.b.cooling@osfhealthcare.org
Colleen J Klein, PhD, APRN
OSF HealthCare System
Interventions
  • Behavioral: digital health delivered multicomponent intervention — The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.
Study Locations (1 sites)
OSF HealthCare System, Peoria, Illinois 61602 United States
Eligibility Criteria
Inclusion Criteria: * Patient of one of four medically qualified health care centers and/or OSF HealthCare as defined by insurance type * Insured by Medicaid or dually eligible for Medicare or Medicaid * Has one or more of the three following conditions: Hypertension, Diabetes Mellitus, or Pregnancy * Able to read and understand English or read translated materials in language provided (e.g. Spanish) * Minors who are pregnant and less 18 years of age who are enrolled in the MIC Program Exclusion Criteria: * Not enrolled in the MIC Program * No one will be excluded on basis of sex or race
Conditions Bronchial Asthma
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn about the frequency needed for stepping-up treatment in patients with mild and moderate bronchial asthma. The main questions this study aims to answer are: * What is the frequency and duration in which patients of asthma need to step up their treatment? * Can the criteria described in this study be applied and validated to test need for step up of asthma treatment? Participants will follow the treatment they are already receiving according to established guidelines and will be asked for regular visits for examination and spirometry. They will record symptoms score, each time they use the prescribed rescu inhaler, and morning and evening peak expiratory flow.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Annualized frequency of asthma step-up (52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-08-21
Completion: 2026-03-30
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ain Shams University
Principal Investigators:
  • Hesham H Raafat, M.D. (PRINCIPAL_INVESTIGATOR) - Security Forces Hospital Dammam
Contact Information
Study Contact:
Hesham H Raafat, M.D.
00966592542751
hesham.raafat@med.asu.edu.eg
HESHAM H RAAFAT, M.D.
00966592542751
hesham.raafat@med.asu.edu.eg
Security Forces Hospital Dammam
NAJLAA S ALAYED, MsC, head of RT
Security Forces Hospital Dammam
Interventions
N/A
Study Locations (1 sites)
Security Forces Hospital Dammam, Dammam, Saudi Arabia
Eligibility Criteria
Inclusion Criteria: 1. Able to give written informed consent. 2. Age above 12 years. 3. Ability to use study inhalers correctly, use e-diary, and comply with study procedures and visits. 4. Confirmed diagnosis of mild or moderate asthma asthma (based on GINA defined asthma control on a maximum of maintenance low dose ICS/LABA combination). 5. Pre-bronchodilator ≥FEV1 60%. 6. Reversibility test ≥12% or 200 ml from baseline. 7. Non-smoker. 8. For female subjects, non-pregnant and administer efficient contraception if in childbearing period. Exclusion Criteria: 1. Severe asthma exacerbation in last 3 months. 2. Use of any systemic corticosteroids in last 12 weeks. 3. Use of depot systemic steroids in last 12 weeks. 4. Any concurrent respiratory disease as bronchiectasis, COPD, lung fibrosis, … 5. Current or known history of tuberculosis in any organ. 6. Current malignancy or any history of malignant disease for the past 5 years. 7. Subjects receiving any medications with known drug interaction with study medications. 8. Use of beta-blockers including eye drops. 9. Any significant concurrent disease as cardiac, hepatic, renal, … 10. Current or history of alcohol or drug abuse. 11. Current or history of significant psychiatric disease. 12. Current or history of significant immunodefieciency. 13. History of receiving any biological therapy for asthma for the last 3 years or currently eligible for any biological therapy for asthma. 14. Subjects under any immuno-modulating therapy including biological therapy for any other indication. Subjects may be allowed to participate after 5 times half-live of the concerned drug. 15. Any known allergy or contraindication to any of the study medications.
Conditions Brain Metastases, Adult, Non Small Cell ...
Phase NA
Enrollment 70
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Silibinin — Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
  • Other: Placebo — Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC

Primary Outcomes

  • intracranial local recurrence (up to 12-24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-01
Completion: 2027-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: A.O.U. Città della Salute e della Scienza
Contact Information
Study Contact:
Pierangela Botta
+390116334904
botta.neuro.oncologia@gmail.com
Alessia Pellerino, M.D., Ph.D.
+390116334904
alessia.pellerino85@gmail.com
Elisa Bennicelli, M.D.
elisa.bennicelli@hsanmartino.it
Unità Operativa di Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino di Genova
Interventions
  • Dietary Supplement: Silibinin — Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
  • Other: Placebo — Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
Study Locations (6 sites)
Unità Operativa di Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino di Genova, Genova, Italy
Neurosurgery Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy
Institute of Neurosurgery, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Catholic University, Rome, Italy
Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy
Precision Medicine in Breast Cancer Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, 10126 Italy
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed BM from NSCLC or BC by local pathology * Single BM (maximum diameter of 3 cm) on MRI before surgery * Complete surgical resection (MRI-verified within 14 days prior randomization) * pSTAT3 score in reactive astrocytes of peritumoral tissue confirmed by local or central assessment * patient must have recovered from the effects of surgery, including post-operative infection, suture/stample removal from brain surgery and wound healing before randomization * ≥ 18 - 70 years of age * Karnofsky performance status ≥ 70 at assessment ≤ 14 days prior to randomization * patient has adequate bone marrow, renal, and hepatic function ≤ 21 days prior to randomization as follows: 1. absolute neutrophil count (ANC) ≥ 1500/mm3 2. platelets ≥ 100000/ mm3 3. Hemoglobin ≥ 9.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin ≥ 9.0 g/dl is acceptable) 4. renal function: calculated creatinine clearance ≥ 30 ml/min by the Cockcroft-Gault formula 5. hepatic function: total bilirubin ≤ 1.5 times upper limit of normal (ULN), aspartate aminotransferase (AST), and alanine transferase (ALT) ≤ 3 times ULN. Subjects with Gilbert's syndrome documented in medical history may be enrolled if total bilirubin is \< 3 times ULN * Electrocardiogram (ECG) without evidence of acute cardiac ischemia ≤ 21 days prior to randomization * Female subject of childbearing potential (i.e. those who are not postmenopausal for at least 1 year or surgically sterile by bilateral salpingectomy, bilateral oophorectomy or hysterectomy) should practice at least one accepted method of birth control listed below during study entry, for the entire duration of the study and for at least 6 months after treatment with silibinin has ended. Male subjects should practice at least one accepted method of birth control listed below during study entry, for the entire duration of the study and for at least 6 months after treatment with silibinin has ended. If using a condom, practice at least one other method of birth control listed below during the study for at least 6 months after silibinin treatment: * Combined (estrogen and progesterone contained) hormonal contraception (oral, intravaginal, transdermal) associated with the inhibition of ovulation * Progesterone-only hormonal contraception (oral, intravaginal, transdermal) associated with the inhibition of ovulation * Bilateral tubal occlusion/ligation * True abstinence: refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject * A vasectomized male subject or a vasectomized partner of a female subject * Intrauterine device, IUD (females) * Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream) unless not deemed acceptable as highly effective contraception by local regulations * Women of child-bearing potential must have a negative pregnancy test (urine o serum) within 7 days prior the randomization * Must voluntarily sign and date informed consent form, for both tumor tissue biomarker testing and study participation, approved by an Independent Ethic Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures Exclusion Criteria: * Absence of expression of STAT3 on the reactive astrocytes of brain metastases * Incomplete surgical resection and/or diameters \> 3 centimeters of brain metastasis before surgery * Brain metastases that previously received any type of radiation therapy * Progressive systemic disease requiring a change of the antineoplastic therapy * Prior invasive malignancy (except for non-melanomatous skin cancer, oral cavity, or cervix) unless disease free for ≥ 2 years * Prior, concomitant, or planned treatment with experimental agents * Patients has had major immunologic reaction * Patient has had a history of hypersensitivity to silibinin or excipient * Patient is unsuitable to receive steroids * Patient is a lactating or pregnant female * Severe, active co-morbidity, defined as follows: * Severe hepatic impairment (Child-Pugh C or higher \[score of 10 or higher\]); subject with mild or moderate hepatic impairment (Child-Pugh score of 5-9) may be eligible for treatment * Unstable angina and/or congestive heart failure within the last 6 months * Transmural myocardial infarction within the last 6 months * Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations ≥ 2 mm using the analysis of an EKG performed within 21 days prior to enrollment * New York Heart Association grade2 or greater congestive heart failure requiring hospitalization within 12 months prior to enrollment * History of stroke, cerebral vascular accident or transient ischemic attack within 6 months * Serious and inadequately controlled cardiac arrhythmia * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of enrollment * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of enrollment * Subject with clinically defined Acquired Immune-Deficiency Syndrome (AIDS)-defining illness. This is necessary to ensure subjects are likely to be able to receive silibinin plus standard of care according to the systemic disease * Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the Investigator may put the subject at high risk of toxicity * Any other major medical illnesses or psychiatric impairments that in the Investigator's opinion will prevent administrations or completion of protocol therapy * Patient treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study except intra-operative therapy to guide resection or experimental imaging without therapeutic intent * Inability to undergo contrast-enhanced MRI scans
Conditions Hypertension, Left Ventricular Hypertrop...
Phase PHASE4
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Eplerenone — After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
  • Drug: Chlorthalidone — After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
  • Drug: Potassium — After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.

Primary Outcomes

  • Change in myocardial flow reserve (9 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-08-25
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brigham and Women's Hospital
Principal Investigators:
  • Gail K Adler, MD, PhD (PRINCIPAL_INVESTIGATOR) - Brigham and Women's Hospital
Contact Information
Study Contact:
Gail K Adler, MD, PhD
781-223-2686
gadler@bwh.harvard.edu
Gail K Adler, MD, PhD
617-732-6660
gadler@partners.org
Brigham and Women's Hospital
Gail K Adler, MD, PhD
Brigham and Women's Hospital
Interventions
  • Drug: Eplerenone — After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
  • Drug: Chlorthalidone — After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
  • Drug: Potassium — After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
Study Locations (1 sites)
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: 1. History of hypertension 1. Seated systolic BP \< 180 mmHg and diastolic \< 110 mmHg if on antihypertensives 2. Seated systolic BP 141-200 mmHg and/or diastolic BP 90-114 mmHg if not on antihypertensives 2. LVH by echocardiogram 1. For men: interventricular septum thickness ≥ 12mm 2. For women: interventricular septum thickness ≥ 11mm 3. We will also allow inclusion of people with treated hypothyroidism, pre-diabetes and diabetes controlled by diet, exercise, and/or metformin. Exclusion Criteria: * Use of MR antagonist (eplerenone, spironolactone, or finerenone) or amiloride (amiloride inhibits ENaC, which is a key mediator of MR's actions) within the past year * Orthostatic hypotension * Major medical illness, including uncontrolled diabetes mellitus (Hemoglobin A1c \>7.5) * LV ejection fraction \< 40% * New York Heart Association class III to IV congestive heart failure or unstable angina * A history in the prior 6 months of Q-wave myocardial infarction, stroke, transient ischemic attack, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft * History of secondary hypertension * Known genetic cardiomyopathy * Renal disease (seum creatinine \>1.5 mg/dL for men and \>1.3 mg/dL for women) * Hepatic disease * Bronchospastic lung disease * Alcohol or substance abuse * Hormone replacement therapy * Abnormal values for electrolytes, liver enzymes or TSH * Pregnancy or lactation * All individuals \<18 and \>75 years will be excluded due to safety concerns of administering an angiotensin-II infusion in these patient groups.
Conditions Opioid Use, Breast Cancer
Phase NA
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research study will evaluate the use of, and participants experience with, a new device called Addinex that safely stores and dispenses opioid medication. The purpose of this study is to evaluate the use of the Addinex device in cancer patients undergoing cancer-related surgery that require pain control with opioids after the surgery. Participants will be asked to answer questions about their medical history and background, fill out questionnaires, use a mobile application associated with the device, and undergo a phone interview one month after stopping use of the device. This study aims to find out how participants like using the Addinex device as opposed to a traditional pill bottle. Results of this study will help determine if the Addinex device could be useful to patients in the future after surgeries, as opposed to typical pill bottles.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Device: Addinex Device (ADX-27) — The device operates without the use of any electronics, wireless or firmware requirements. This is achieved through its mechanical system which uses a different randomized "passcode" for each dose that is loaded into a circular drum inside the device. The "passcodes" are provided by an online server through either a mobile app, web app, text service or call in service. The online server provides "passcodes" on a request basis, while following instructions set by the treating physicians.

Primary Outcomes

  • Rate of Device Return (12 weeks)
  • Rate of Unused Pill Disposal (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-10-05
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Columbia University
Collaborators: National Institute on Drug Abuse (NIDA)
Principal Investigators:
  • Dawn Hershman, MD (PRINCIPAL_INVESTIGATOR) - Columbia University
Contact Information
Study Contact:
Research Nurse Navigator
212-342-5162
cancerclinicaltrials@cumc.columbia.edu
Dawn Hershman, MD
212-305-1945
dlh23@cumc.columbia.edu
Columbia University Medical Center
Interventions
  • Device: Addinex Device (ADX-27) — The device operates without the use of any electronics, wireless or firmware requirements. This is achieved through its mechanical system which uses a different randomized "passcode" for each dose that is loaded into a circular drum inside the device. The "passcodes" are provided by an online server through either a mobile app, web app, text service or call in service. The online server provides "passcodes" on a request basis, while following instructions set by the treating physicians.
Study Locations (1 sites)
Columbia University Medical Center, New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Adult patients (age greater than or equal to 18 years) * Planned for major cancer-related surgery and expected to receive a postoperative opioid prescription * Must speak English or Spanish * Must have access to a smartphone or an alternative smart device (e.g., iPhone, Android phone, iPad, Surface, etc.). * Co-enrollment in trials involving pharmacologic therapy is allowed Exclusion Criteria: * Patients who are taking opioids daily prior to the surgical procedure * Patients unable to physically utilize the device * Patients unable to self-administer medications * Patients uncomfortable with using iPhone or iPad-based technology
Conditions Pediatric Obesity, Pediatric Asthma
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-center, randomized, SHAM-controlled, parallel assignment, double-masked,8-week interventional study among children aged 8-17 years (not yet 18 years old) of age with obesity and asthma. (n=60), recruited from Duke Health Center Creekstone, to test the effectiveness of inspiratory muscle rehabilitation (IMR) as an acceptable add-on intervention to reduce dyspnea (feeling short-of-breath or breathless) and to promote greater activity in children with obesity and asthma. Clinic to test the effectiveness of inspiratory muscle rehabilitation (IMR) as an acceptable add-on intervention to reduce dyspnea (feeling short-of-breath or breathless) and to promote greater activity in children with obesity

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Pro2 - 60% of participant's MIP — Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP.
  • Device: Pro2 - 15% of participant's MIP — Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition

Primary Outcomes

  • Adherence to active IMR Adherence to active IMR (approximately 2 months)
  • Participant satisfaction among active IMR participants (approximately 2 months)
  • Prevalence of completer status (approximately 2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-27
Completion: 2026-06
Eligibility
Age: 8 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Collaborators: American Lung Association
Principal Investigators:
  • Jason Lang, MD (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
Veronica Carrion, BS
9197041523
vmp19@duke.edu
Jasong Lang, MD
9196843364
jason.lang@duke.edu
Veronica Carrion, BS
9197041523
vmp19@duke.edu
Duke Healthy Lifestyles Clinic
Interventions
  • Device: Pro2 - 60% of participant's MIP — Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP.
  • Device: Pro2 - 15% of participant's MIP — Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition
Study Locations (1 sites)
Duke Healthy Lifestyles Clinic, Durham, North Carolina 27704 United States
Eligibility Criteria
Inclusion Criteria: * Documented informed consent from legal guardian and assent from participant as appropriate. * Children 8 to 17 years of age with obesity (BMI ≥ 95th percentile for age and sex) and mild asthma. * Participants (or parent/guardian) must have access to the internet and an approved smart device/computer. * Child must have a designated caregiver who expresses a commitment to encourage the participant to complete the study procedures. * Participant and legal guardian must speak and read English. * Child is currently taking prescription medicine for asthma (Any type of albuterol or inhaled steroid) Exclusion Criteria: * Prior intubation for asthma * Current self-reported pregnancy or planning to become pregnant. * Have an FEV1 \< 50% of predicted at screening * History of lung surgery in the past two years, * History of pulmonary embolism in the past two years, * Any history of recurrent spontaneous pneumothorax, or pneumothorax in the past 12 months * Current undiagnosed chest pain, * History of inner ear surgery in the past 12 months, * Undiagnosed syncopal episodes in the past two years, * Progressive neurological or neuromuscular disorders or need for chronic O2 therapy. * Inability to complete baseline measurements satisfactorily according to the research coordinator's or PI's judgment. * Any condition in the opinion of the PI that would not allow safe conduct of study procedures (including IMR, MIP testing or step-test), such as a physical disability, recent musculoskeletal injury or illness, current and ongoing evaluation for undiagnosed cardiopulmonary or neurologic symptoms
Conditions Type 2 Diabetes
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an interventional study that will evaluate the feasibility, implementation, and efficacy of an online, 12-week, plant-based, nutrition education program in a community setting. Data will also be analyzed to see if participation in the program results in reductions glycated hemoglobin levels, body weight, and cholesterol levels.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: plant-based diet — For the duration of the study, this arm will: follow a low-fat vegan diet; weigh themselves weekly, and get fasting bloodwork before, during and after the study

Primary Outcomes

  • Glycated hemoglobin (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-21
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Physicians Committee for Responsible Medicine
Principal Investigators:
  • Neal Barnard, MD (PRINCIPAL_INVESTIGATOR) - Physicians Committee for Responsible Medicine
Contact Information
Study Contact:
VANITA RAHMAN, MD
2025277500
vrahman@pcrm.org
Roxanne Becker, MBChB
2022779760
rbecker@pcrm.org
VANITA RAHMAN, MD
202-527-7500
vrahman@pcrm.org
Physician Committee for Responsible Medicine
Interventions
  • Behavioral: plant-based diet — For the duration of the study, this arm will: follow a low-fat vegan diet; weigh themselves weekly, and get fasting bloodwork before, during and after the study
Study Locations (1 sites)
Physician Committee for Responsible Medicine, Washington D.C., District of Columbia 20016 United States
Eligibility Criteria
Inclusion Criteria: * U.S. Men and women meeting the age of majority, defined as follows: Age 19 or older in Nebraska and Alabama; Age 21 or older in Mississippi; Age 18 or older in all other states * Prior diagnosis of type 2 diabetes mellitus Exclusion Criteria: * Use of recreational drugs in the past 6 months * Pregnancy or intention to become pregnant during the study period, as verified by self-report * Unstable medical or psychiatric illness * Lack of English fluency * Inability to maintain current medication regimen * Inability or unwillingness to participate in all components of the study